4Filed Sep 8, 8:00 PM ET

CV Sciences (CVSI) 10% Owner Charlie E. Cheever III Buys Shares

$CVSI · CV Sciences, Inc.

Research Summary

AI-generated summary of this SEC filing

Updated

CV Sciences (CVSI) 10% Owner Charlie E. Cheever III Buys Shares

What Happened
Charlie E. Cheever III, a reported 10% owner of CV Sciences, acquired a total of 5,740,816 shares of CVSI in a series of purchases executed between 2026-07-16 and 2026-08-07. Each purchase was at approximately $0.02 per share, totaling roughly $114,800–$115,000. These were purchases (transaction code P), which investors often view as a more informative/bullish signal than routine sales.

Key Details

  • Transaction type: Open market/private purchases (Code: P).
  • Date range: 2026-07-16 through 2026-08-07.
  • Per-trade summary (shares @ $0.02 each; reported value):
    • 2026-07-16: 91,387 shares — $1,828
    • 2026-07-17: 749,000 shares — $14,980
    • 2026-07-21: 335,000 shares — $6,700
    • 2026-07-22: 272,500 shares — $5,450
    • 2026-07-24: 470,075 shares — $9,402
    • 2026-07-28: 1,830,000 shares — $36,600
    • 2026-07-29: 60,000 shares — $1,200
    • 2026-07-31: 1,730,000 shares — $34,600
    • 2026-08-04: 108,000 shares — $2,160
    • 2026-08-07: 94,854 shares — $1,897
  • Total acquired: 5,740,816 shares for ~ $114,817.
  • Shares owned after transaction: Not specified in the provided filing details.
  • Footnotes/plan: No 10b5-1 plan, tax-withholding, or other footnotes were provided in the summary you supplied.
  • Timeliness: Filing date 2026-09-09 for trades through 2026-08-07 — the Form 4 appears to have been filed late (may have timeliness implications).

Context

  • As a 10% owner (not necessarily an executive), Cheever is a significant holder; purchases increase his stake but do not by themselves indicate company performance.
  • These were straightforward purchases (not option exercises, gifts, or awards). No immediate resale or cashless exercise was reported.
  • Investors often view insider purchases as a positive signal, but this should be weighed with other company fundamentals and disclosures.